Nestlé sold its mainstream Vitamins, Minerals and Supplements business and Holistic Health portfolio to Yellow Wood Partners for $1 billion in a transaction that closes a three-year strategic reset. The deal removes Garden of Life, Pure Encapsulations, Vital Proteins, and Nuun from Nestlé's consumer health division. Yellow Wood Partners, a $2.6 billion AUM middle-market firm based in Boston, now owns the fourth-largest VMS platform in North America by retail velocity.

The Swiss parent retains its medical nutrition arm—including Boost and Peptamen clinical formulas—and exits the crowded direct-to-consumer supplement category where Amazon private label and vertical DTC brands compressed margins by 340 basis points since 2021. Nestlé's health science revenue peaked at $4.1 billion in 2022 before the company began separating pharmaceutical-adjacent products from lifestyle wellness. The vitamins unit generated approximately $850 million in trailing revenue with mid-teens EBITDA margins, below Nestlé's 18.2% group average. Yellow Wood paid roughly 1.2x revenue, a 15% discount to the 1.4x median for recent consumer health carve-outs.

This carve-out matters because it signals where institutional capital sees defensible moats in consumer health. Nestlé keeps the hospital-channel and clinical nutrition assets where reimbursement codes and regulatory barriers protect pricing. Yellow Wood inherits brands with strong retail distribution but commoditizing formulations—Garden of Life competes with 47 other probiotic SKUs at Whole Foods, and Vital Proteins faces collagen powder competition from brands that didn't exist in 2020. The PE firm's thesis likely centers on operational consolidation and a 24-to-36 month margin expansion play before a strategic sale to a platform like Bayer Consumer Health or a SPAC in the next upcycle.

Allocators should note Nestlé's retained assets now sit inside a tighter health science perimeter with $3.2 billion in revenue, 22% EBITDA margins, and exposure to GLP-1 tailwinds through medical nutrition for bariatric patients. Yellow Wood's existing portfolio—including Vega protein and MegaFood—suggests the firm will pursue revenue synergies in shared retailer programs and back-end procurement savings of $40-60 million annually. The deal also removes a business unit that required $120 million in annual digital marketing spend to defend share against DTC insurgents.

Watch for Yellow Wood's first 100-day integration memo and whether the firm consolidates manufacturing across its three VMS platforms or continues dual-track operations. Nestlé's next earnings call in mid-April will clarify how the company reallocates the $1 billion in proceeds—likely toward its $20 billion share buyback program announced in February or bolt-on acquisitions in weight management adjacencies. The medical nutrition segment now represents 11% of Nestlé Health Science revenue but 19% of divisional EBITDA, a margin profile that justifies the carve-out arithmetic.